Literature DB >> 15712606

Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans.

William C Uicker1, Hester A Doyle, James P McCracken, Mary Langlois, Kent L Buchanan.   

Abstract

Cryptococcus neoformans is a yeast that causes cryptococcosis, a life-threatening disease that develops following inhalation and dissemination of the organisms. C. neoformans has a predilection for the central nervous system (CNS) and mortality is most frequently associated with meningoencephalitis. Susceptibility to cryptococcosis is increased in patients with deficiencies in cell-mediated immunity (CMI). Because cryptococcal CNS infections are associated with mortality and diagnosis of cryptococcosis is often not made until after dissemination to the CNS, a better understanding of host defense mechanisms against C. neoformans in the CNS is needed to design improved therapies for immunocompromised individuals suffering from cryptococcosis. Using a mouse model, we previously described a protective cell-mediated immune response induced in the periphery that limited the growth of C. neoformans in the CNS. In the current investigation, we examined cytokine and chemokine expression in the CNS to identify factors important in achieving protective immunity. We observed increased expression of IL-1beta, TNF-alpha, IFN-gamma, MCP-1, RANTES, and IP-10 in C. neoformans-infected brains of immune mice compared to control mice suggesting that these cytokines and chemokines are associated with the protective immune response. Furthermore, the Th1-type cytokines TNF-alpha and IFN-gamma, but not the Th2 cytokines IL-4 and IL-5, were secreted at significantly higher levels in C. neoformans-infected brains of immune mice compared to control mice. Our results demonstrate that cytokines and chemokines associated with CMI are produced following infection in the CNS of immunized mice, and the expression of these factors correlates with protection against C. neoformans in the CNS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712606     DOI: 10.1080/13693780410001731510

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  21 in total

Review 1.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.

Authors:  Joseph N Jarvis; Graeme Meintjes; Kevin Rebe; Gertrude Ntombomzi Williams; Tihana Bicanic; Anthony Williams; Charlotte Schutz; Linda-Gail Bekker; Robin Wood; Thomas S Harrison
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

3.  Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia.

Authors:  Stanislaw Schmidt; Lars Tramsen; Mitra Hanisch; Jean-Paul Latgé; Sabine Huenecke; Ulrike Koehl; Thomas Lehrnbecher
Journal:  J Infect Dis       Date:  2010-12-14       Impact factor: 5.226

4.  Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysis.

Authors:  S M Lofgren; D J Bond; N Nakasujja; D R Boulware
Journal:  AIDS Behav       Date:  2020-06

5.  Treatment with IP-10 induces host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice.

Authors:  Gaurav Gupta; Saikat Majumdar; Anupam Adhikari; Parna Bhattacharya; Asok Kumar Mukherjee; Suchandra Bhattacharyya Majumdar; Subrata Majumdar
Journal:  Med Microbiol Immunol       Date:  2011-05-01       Impact factor: 3.402

6.  The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.

Authors:  Krishanthi S Subramaniam; Kausik Datta; Eric Quintero; Catherine Manix; Matthew S Marks; Liise-Anne Pirofski
Journal:  J Immunol       Date:  2010-04-19       Impact factor: 5.422

7.  New insights on the pathogenesis of invasive Cryptococcus neoformans infection.

Authors:  Helene C Eisenman; Arturo Casadevall; Erin E McClelland
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

8.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

9.  IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis.

Authors:  Werner Stenzel; Uwe Müller; Gabriele Köhler; Frank L Heppner; Manfred Blessing; Andrew N J McKenzie; Frank Brombacher; Gottfried Alber
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

10.  Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis.

Authors:  Qing Zhou; Ruth A Gault; Thomas R Kozel; William J Murphy
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.